These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33739311)

  • 1. A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Islam RM; Davis SR; Bell RJ; Tejada-Berges T; Wrede CD; Domchek SM; Meiser B; Kirk J; Krejany EO; Hickey M
    Menopause; 2021 Mar; 28(7):748-755. PubMed ID: 33739311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Hickey M; Moss KM; Brand A; Wrede CD; Domchek SM; Meiser B; Mishra GD; Joffe H
    Gynecol Oncol; 2021 May; 161(2):527-534. PubMed ID: 33583580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women.
    Hickey M; Trainer A; Braat S; Davey MA; Krejany E; Wark J
    BMJ Open; 2017 Nov; 7(11):e018758. PubMed ID: 29138210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Hickey M; Moss KM; Mishra GD; Krejany EO; Domchek SM; Wark JD; Trainer A; Wild RA
    Gynecol Oncol; 2021 Jul; 162(1):88-96. PubMed ID: 33972087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.
    Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
    Menopause; 2020 Jan; 27(1):26-32. PubMed ID: 31613831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of bone density and bone strength following premenopausal risk-reducing bilateral salpingo-oophorectomy: a prospective controlled study (WHAM Study).
    Jiang H; Robinson DL; Lee PVS; Krejany EO; Yates CJ; Hickey M; Wark JD
    Osteoporos Int; 2021 Jan; 32(1):101-112. PubMed ID: 32856124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
    Kershaw V; Hickey I; Wyld L; Jha S
    Eur J Obstet Gynecol Reprod Biol; 2021 Oct; 265():7-17. PubMed ID: 34416580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
    Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
    Menopause; 2020 Jan; 27(1):20-25. PubMed ID: 31567874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
    Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
    Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies.
    Hickey I; Jha S; Wyld L
    Gynecol Oncol; 2021 Mar; 160(3):763-770. PubMed ID: 33317909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
    Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
    Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
    Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    Crosbie EJ; Flaum N; Harkness EF; Clayton RD; Holland C; Martin-Hirsch P; Wood N; Keating P; Woodward ER; Lalloo F; Donnai P; Edmondson RJ; Evans DG
    Int J Cancer; 2021 Mar; 148(5):1155-1163. PubMed ID: 33152107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of female sexual function in women who underwent abdominal or vaginal hysterectomy with or without bilateral salpingo-oophorectomy.
    Doğanay M; Kokanalı D; Kokanalı MK; Cavkaytar S; Aksakal OS
    J Gynecol Obstet Hum Reprod; 2019 Jan; 48(1):29-32. PubMed ID: 30445203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
    Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    Hickey M; Moss KM; Krejany EO; Wrede CD; Domchek SM; Kirk J; Brand A; Trainer A; Mishra GD; Baker FC
    Gynecol Oncol; 2021 Aug; 162(2):447-453. PubMed ID: 34116835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study.
    Brotto LA; Branco N; Dunkley C; McCullum M; McAlpine JN
    J Obstet Gynaecol Can; 2012 Feb; 34(2):172-178. PubMed ID: 22340066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral Salpingo-oophorectomy and Breast Cancer Risk for
    Conduit C; Milne RL; Friedlander ML; Phillips KA
    Cancer Prev Res (Phila); 2021 Nov; 14(11):983-994. PubMed ID: 34348913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study.
    Mai PL; Miller A; Black A; Falk RT; Boggess JF; Tucker K; Stuckey AR; Rodriguez GC; Wong C; Amatruda TT; Wilkinson KJ; Modesitt SC; Yamada SD; Bixel KL; Glaser GE; Rose PG; Greene MH; Sherman ME
    Am J Obstet Gynecol; 2022 Jul; 227(1):61.e1-61.e18. PubMed ID: 35216968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.
    Gaba F; Robbani S; Singh N; McCluggage WG; Wilkinson N; Ganesan R; Bryson G; Rowlands G; Tyson C; Arora R; Saridogan E; Hanson H; Burnell M; Legood R; Evans DG; Menon U; Manchanda R;
    Int J Gynecol Cancer; 2021 Feb; 31(2):286-291. PubMed ID: 32907814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.